Artios, a Cambridge-based biotech group researching the right way to goal the DNA harm response (DDR) in most cancers, has efficiently closed an oversubscribed $115m (£87.3m) Sequence D spherical.
The brand new funding will assist the agency’s lead programme, known as alnodesertib, which is inspecting therapies for pancreatic and colorectal cancers.
With the Sequence D closed, Artios may provoke the second part of medical trials for its remedy focusing on breast most cancers, known as ART6043.
“This Sequence D accelerates our potential path to registration for each alnodesertib and ART6043, broadening improvement for the subsequent technology of DDR therapeutics to indications among the many highest of unmet want throughout pancreatic, colorectal, and breast cancers, the place median survival is commonly measured in months,” stated Mike Andriole, chief govt of Artios.
The funding spherical was co-led by SV Well being Traders and RA Capital Administration and included participation from new backer Janus Henderson Traders.
“We’re thrilled to have supported Artios’ evolution, from an early-stage DDR pioneer once we based the corporate to the established firm it has turn into, distinguished by a promising and differentiated pipeline,” stated SV Well being Traders managing accomplice Nikola Trbovic.
“We sit up for persevering with to take action because it deploys the Sequence D proceeds to drive late-stage improvement of alnodesertib in addition to its pipeline.”
